COMBINATION OF WEEKLY RADIATION AND DOCETAXEL FOR LOCALLY ADVANCED NON SMALL CA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。局部晚期或无法切除的非小细胞肺癌(NSCLC)被认为是一种预期寿命不到两年的不治之症，无论进行何种治疗。许多II期患者和大多数III期非小细胞肺癌患者最初是通过手术或偏远部位的放射复发来控制的。这被认为是由于在最初诊断时，在局部肿瘤引流淋巴系统内或在偏远部位存在恶性细胞。局部治疗方式，如肿瘤照射和全身化疗，在控制疾病进展方面显然无效。直到最近，治疗局部晚期非小细胞肺癌的益处一直存在争议，因为一些研究并没有显示出比根本不治疗更能提高存活率。然而，治疗是由于与治疗相关的生活质量的改善而提供的。目前，大多数肿瘤学家为这些患者提供化疗、放疗或两者兼而有之。这是假设，全身和局部控制的疾病可以通过联合放射和化疗，随后或同时进行。这项研究的目的是调查在放射治疗前一天联合使用泰索帝的耐受性是否良好，并且与传统的放射治疗相比，是否会导致癌症缩小。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Locally advanced or unresectable non-small cell lung cancer (NSCLC) is considered an incurable disease with a life expectancy of less than two years regardless of treatment. Many patients with stage II and most with stage III NSCLC are initially controlled with surgery or radiation relapse at a remote site. This is believed to be due to the presence of malignant cells within the local tumor draining lymphatic system or at remote sites at the time of initial diagnosis. Local treatment modalities such as tumor irradiation as well as systemic chemotherapy have been clearly ineffective in controlling disease progression. Until recently, the benefit of treating locally advanced NSCLC has been controversial since some studies did not show improved survival over no treatment at all. Nevertheless, treatment was offered due to improved quality of life associated with treatment. Chemotherapy, radiation or both in succession are presently offered by most oncologist to these patients. It was hypothesized that both systemic and locoregional control of the disease could be improved by combining radiation and chemotherapy, subsequentially or concomitantly. This study aims to investigate if the combination of the drug Taxotere given one day before radiation is well tolerated and will result in enhanced shrinkage of the cancer as compared to traditional radiation therap